TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

22 июн 2022 16:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

08 июн 2022 16:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

01 июн 2022 16:05:01 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates

16 май 2022 16:05:01 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

04 апр 2022 16:05:00 Источник Nasdaq GlobeNewswire

Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201

21 мар 2022 16:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

03 мар 2022 16:05:01 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference

28 фев 2022 16:05:01 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer

06 янв 2022 07:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

03 янв 2022 16:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

15 ноя 2021 16:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

12 ноя 2021 07:05:00 Источник Nasdaq GlobeNewswire

Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501

09 ноя 2021 16:05:01 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

18 окт 2021 16:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

05 окт 2021 16:05:00 Источник Nasdaq GlobeNewswire

Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors

28 сен 2021 16:05:00 Источник Nasdaq GlobeNewswire

Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

08 сен 2021 07:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

02 сен 2021 16:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

16 авг 2021 16:05:00 Источник Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

03 авг 2021 16:05:00 Источник Nasdaq GlobeNewswire